• BIA Blog

CEO Update: Monday 18 June

Last week we saw some great news for our sector. The £2.5 billion British Patient Capital fund, launched by the British Business Bank, will provide long-term funding to support the growth of innovative UK bioscience companies and other sectors and will help to build the next generation of UK life science companies to scale to global leadership.

Video of the week: Opportunities for UK Life Sciences companies in China

Find out how the business and regulatory environment is changing, and hear from Department for International Trade experts based in China, from UK Life Sciences companies who have invested there and from organisations in China who can help with advice and incubation services.

CEO Update: Monday 11 June

Last week, the BIA was out in Boston for BIO 2018. UK companies became Official World record holders, showcasing UK excellence, and partnering and engaging with the international biotech community.

A strategy for clean growth: the potential of industrial biotech

The following guest blog is from Dr Jen Vanderhoven, Senior Project Manager for FUJIFILM Diosynth Biotechnologies, and Dr Mark Corbett, Network Manager for BIOCATNET, a BBSRC Network in Industrial Biotechnology and Bioenergy.

BIA City and Finance Update May 2018

Last month saw two deals and continued strong financing in the sector with over £200m raised for UK-based businesses. Also, in this edition, we explain the UK’s tax efficient investing schemes, look at the first ICO in Europe, and meet Maven, an investor in high growth businesses.

CEO Update Monday 4 June 2018

This week I’m writing from BIO in Boston, one of the largest life science conferences of the year, where BIA has meetings, panels and networking lined up to highlight the strengths of the UK bioscience sector.

Recognising the potential of SMEs in combating AMR

By Ian Staples, founder and chief executive of British biotechnology company Matoke Pharma. Ian discusses the need to support the vital contribution small and medium sized enterprises (SMEs) make to the fight against anti-microbial resistance

Guest blog: ‘Diversity in STEM: why it matters more than ever’ – By Gillian Burgess

Dr Gillian Burgess, Site Head of UK Research and Vice President at Vertex Pharmaceuticals and Board Member of the Science Industry Partnership (SIP) of employers, sets out the business case for keeping up the momentum on diversity across the science industries.

BIA analysis of the Office for Life Sciences 'Strength and Opportunity' and 'Life Sciences Competitiveness Indicators' data

Last week the government produced two reports looking at the vital statistics of the UK life sciences industry and the international competitiveness of the UK environment for life sciences businesses. Here we take a brief look at the data and pick out some interesting statistics.

CEO update: Monday 21 May

Today the PM delivered a speech on the vital role AI can have in diagnosing chronic diseases and challenged the NHS, the AI sector and health charities to use data and AI to drastically improve current diagnosis capabilities to prevent 22,000 cancer deaths each year by 2033.